Drugs / CCI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04823897 | Jul 2021 → Dec 2027 expected | cancer of unknown primary site | PharmaMatrix Holdings Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04823897 ↗ |
| Modality | Small molecule | “CCI-001 is a novel colchicine derivative” NCT04823897 ↗ |
| Route | Intravenous | “CCI-001 will be given intravenously starting at 1.2mg/m2” NCT04823897 ↗ |